Clinical trials: Metabolism and Excretion
Solid Malignancies
Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase
This Phase 1, open label, single centre, non-randomised study in patients with advanced solid malignancies consists of two parts: 1.
- Trial name
- 14C (NCT02640755)
- Testing
- [14C]AZD2014, Multiple dose AZD2014, Fulvestrant
- Where
- United Kingdom
- Volunteers
- 4 people
- Sponsor
- AstraZeneca
Healthy Volunteer
A Phase 1 Study of Mosliciguat in Healthy, Adult Males
This is a single-center, Phase 1, open-label, 3-period, fixed-sequence study to investigate the bioavailability, absorption, metabolism, excretion and the safety of mosliciguat administered to healthy male adults.
- Trial name
- NCT07185321
- Testing
- Mosliciguat, 14C mosliciguat, Dry Powder Inhaler
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Pulmovant, Inc.
Parkinson's Disease (PD)
An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites
The purpose of this study is to determine the rate and routes of excretion of OPC and the mass balance in urine, faeces and expired air.
- Trial name
- NCT02169427
- Testing
- OPC
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Healthy
Open-Label Absorption, Distribution, Metabolism, Excretion (ADME) and Pharmacokinetics (PK) Following a Single Oral Dose of AZD1236 in Healthy Male Subjects
The purpose of this study is to characterise the metabolism, excretion and pharmacokinetics of a single oral dose of [14C] AZD1236 in healthy male subjects.
- Trial name
- NCT01007929
- Testing
- 14C-AZD1236
- Where
- United Kingdom
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2, Kidney Function Tests
The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function.
The purpose of this study is to evaluate how dapagliflozin mechanism of action is impacted by Type 2 Diabetes Mellitus status and kidney function
- Trial name
- DAPASALT (NCT03152084)
- Testing
- Dapagliflozin
- Where
- 4 sites in Netherlands, Sweden
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Breast Cancer, Healthy Volunteers
Study to Determine Absorption, Metabolism, and Excretion of [14C]-SAR439859, and to Assess Absolute Oral Bioavailability of Amcenestrant (SAR439859), in Healthy Post-menopausal Women
Primary Objectives: To assess the excretion balance after oral and IV administration of [14C]-SAR439859 To assess PK of total radioactivity, [14C] -SAR439859 and its metabolite (M7) after IV administration of [14C]-SAR439859 and…
- Trial name
- NCT04940026
- Testing
- amcenestrant, [14C]-SAR439859 microtracer, [14C]-SAR439859
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Sanofi
Healthy Volunteers
A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-DNL343 Following a Single Oral Dose in Healthy Male Participants
This is a Phase 1, open-label, nonrandomized, single-dose study in healthy male participants to investigate the absorption, metabolism and excretion of DNL343.
- Trial name
- NCT06281158
- Testing
- [14C]-DNL343
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Denali Therapeutics Inc.
Healthy Volunteer
Study of the Absorption, Metabolism, and Excretion of [14C]-Ecopipam in Healthy Male Subjects
Phase 1, single-center (United Kingdom), open-label, nonrandomized, single-dose study in healthy adult male subjects to assess the absorption, metabolism, and excretion of [14C]-Ecopipam in Healthy Male Subjects.
- Trial name
- NCT04881955
- Testing
- [14C]-Ecopipam
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Emalex Biosciences Inc.
Type 2 Diabetes Mellitus (T2DM)
A Radiolabeled Mass Balance Study of [14C]-Ertugliflozin (PF04971729, MK-8835) In Healthy Male Participants (MK-8835-038)
This is single dose study of radiolabeled [14C]-ertugliflozin (PF04971729, MK-8835) in healthy male volunteers to study the absorption, distribution, metabolism and elimination of ertugliflozin.
- Trial name
- NCT01127308
- Testing
- Ertugliflozin
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy Male Volunteers
Excretion Balance and Metabolism After a Single Oral Dose of 14C-Labelled ORM-12741
The study is conducted to examine absorption of C14-ORM-12741 from intestine to bloodstream, distribution to bloodstream, metabolism in the liver and excretion of the parent drug and metabolites to faeces, urine and expired air
- Trial name
- ALMAS (NCT00817544)
- Testing
- ORM-12741
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Orion Corporation, Orion Pharma
Cancer
An Absorption, Distribution, Metabolism and Excretion (ADME) Study of Single Oral Dose [14C] GSK2118436 in Subjects With BRAF Mutant Solid Tumors
The study is a Phase 1, open-label study designed to characterize the absorption, distribution, metabolism and excretion of GSK2118436 following administration of a single oral 14C labeled dose of GSK2118436 as a suspension in…
- Trial name
- NCT01262963
- Testing
- GSK2118436
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- GlaxoSmithKline
Healthy Participants
A Trial to Assess the Absorption, Metabolism, Excretion, and Mass Balance of [14C]-Darigabat After a Single Oral Dose in Healthy Male Participants
The primary purpose of this trial is to determine the mass balance, routes, and rates of elimination of total radioactivity and characterize the pharmacokinetics (PK) of darigabat, and total radioactivity in plasma and whole…
- Trial name
- NCT06435923
- Testing
- [14C]-darigabat
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Cerevel Therapeutics, LLC
Healthy Subjects
A Study of the Absorption, Metabolism, and Excretion of [14C]-AMG 510 Following a Single Oral Dose in Healthy Male Subjects
The primary objectives of the study are: to characterize the primary route(s) of elimination of [14C]-AMG 510 and drug-related material, and estimate the overall recovery of radiolabeled material in healthy male participants…
- Trial name
- NCT05578859
- Testing
- AMG 510
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Amgen
ADME
Absorption, Metabolism, and Excretion of (-)-[2-14C]Epicatechin in Humans
The purpose of this study is to determine the absorption, metabolism and excretion of (-)-epicatechin using the radiolabeled tracer (-)-[2-14C]epicatechin in healthy male volunteers observing a flavanol-/procyanidin-controlled…
- Trial name
- NCT01969994
- Testing
- Controlled dietary background, (-)-[2-14C]epicatechin intake
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- The Institutes for Pharmaceutical Discovery, LLC
Chronic Obstructive Pulmonary Disease (COPD)
TD-4208 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects
The purpose of this study is to evaluate the absorption, distribution, metabolism and excretion of an investigational medication used to treat chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT02772159
- Testing
- TD-4208
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Mylan Inc.
Healthy Male Subjects
ADME Study of [14C] Antaitavir Hasophate in Healthy Male Subjects
This is a single-centre, open-label, mass balance and biotransformation study in healthy male subjects utilising a single oral dose of [14C] Antaitavir Hasophate.
- Trial name
- NCT05446233
- Testing
- [14C] Antaitavir Hasophate
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Carcinoma, Non-Small-Cell Lung
A Radiolabeled Mass Balance Study Of [14C]PF-00299804 In Healthy Male Volunteers
This is single dose study of radiolabeled [14C]PF-00299804 in healthy male volunteers to study the absorption, distribution, metabolism and elimination of PF-00299804.
- Trial name
- NCT01034748
- Testing
- [14C]PF00299804
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
Mass Balance Recovery, Absorption, Metabolism and Excretion of [14C]-BLU-5937
This is a single-centre, open-label, non-randomised, single-period, single-dose study in healthy male subjects designed to assess the mass balance recovery, PK, metabolite profile and metabolite identification of [14C]-BLU-5937.
- Trial name
- NCT05244759
- Testing
- [14C]-BLU-5937
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Bellus Health Inc. - a GSK company
Healthy
A Study of Calderasib (MK-1084) Human Absorption, Distribution, Metabolism, and Excretion in Healthy Adult Participants (MK-1084-006)
The purpose of this study is to learn what happens to calderasib in a healthy person's body over time and how it is cleared from the body.
- Trial name
- NCT06687759
- Testing
- [14C]Calderasib
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy Volunteer
Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance Study of [14C] NX-5948
This is a Phase 1, 2-period, open-label, single-dose, fixed-sequence study to assess the absolute bioavailability, absorption, metabolism, excretion, and mass balance of [14C]-NX-5948.
- Trial name
- NCT06691828
- Testing
- NX-5948
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Nurix Therapeutics, Inc.